TY - BOOK
T1 - Interim analysis of COVID-19 vaccine effectiveness against Severe Acute Respiratory Infection due to laboratory-confirmed SARS-CoV-2 among individuals aged 30 years and older, ECDC multi-country study – second update
AU - European Centre for Disease Prevention and Control
AU - ECDC COVID-19 vaccine effectiveness hospital study participants
AU - Aouali, Nassera
AU - Berthet, F.
AU - Braquet, P.
AU - Fagherazzi, G.
AU - Simon, M.
N1 - TECHNICAL REPORT
European Centre for Disease Prevention and Control. Interim analysis of COVID-19 vaccine effectiveness against Severe Acute Respiratory Infection due to laboratory-confirmed SARS-CoV-2 among individuals aged 30 years and older,
ECDC multi-country study – second update. ECDC: Stockholm; 2022.
© European Centre for Disease Prevention and Control, Stockholm, 2022
PY - 2022/3/14
Y1 - 2022/3/14
N2 - This document reports the pooled estimates from the ECDC study of COVID-19 vaccine effectiveness, conducted through the implementation of a multi-country approach using the 'Core protocol for ECDC studies of COVID-19 vaccine effectiveness against hospitalisation with Severe Acute Respiratory Infection laboratory confirmed with SARS-CoV-2, version 1.0'. This second update contains vaccine effectiveness results among individuals aged 30 years and older, for the pre-Delta and the Delta-dominant periods (3 January–31 May 2021 and 1 July–15 December 2021, respectively). It also contains estimates by COVID-19 vaccine product (i.e. Comirnaty and Vaxzevria). Compared with the previous report, two additional countries submitted data retrospectively (Ireland and the Netherlands); therefore, estimates for the pre-Delta period may differ slightly from those published previously.
AB - This document reports the pooled estimates from the ECDC study of COVID-19 vaccine effectiveness, conducted through the implementation of a multi-country approach using the 'Core protocol for ECDC studies of COVID-19 vaccine effectiveness against hospitalisation with Severe Acute Respiratory Infection laboratory confirmed with SARS-CoV-2, version 1.0'. This second update contains vaccine effectiveness results among individuals aged 30 years and older, for the pre-Delta and the Delta-dominant periods (3 January–31 May 2021 and 1 July–15 December 2021, respectively). It also contains estimates by COVID-19 vaccine product (i.e. Comirnaty and Vaxzevria). Compared with the previous report, two additional countries submitted data retrospectively (Ireland and the Netherlands); therefore, estimates for the pre-Delta period may differ slightly from those published previously.
KW - public health report
M3 - Commissioned report
BT - Interim analysis of COVID-19 vaccine effectiveness against Severe Acute Respiratory Infection due to laboratory-confirmed SARS-CoV-2 among individuals aged 30 years and older, ECDC multi-country study – second update
PB - European Centre for Disease Prevention and Control (ECDC)
CY - Stockholm
ER -